

Call: 8th Call - JPIAMR-VRI Network Call 2018

Title: International Research Alliance for Antibiotic Discovery and Development

Acronym: IRAADD

Network composition

Type: C – coordinator P - participant	Name	Institute	Country
C	Rolf Müller	Helmholtz Centre for Infection Research/ Helmholtz Institute for Pharmaceutical Research Saarland	Germany
P	Youming Zhang	Shandong University	China
P	Tilman Weber	Technical University of Denmark	Denmark
P	Philippe Glaser	Institut Pasteur	France
P	Kira Weissman	Université de Lorraine	France
P	Bertrand Aigle	University of Lorraine	France
P	Jean-Luc Pernodet	Institute for Integrative Biology of the Cell, Université Paris-Saclay	France
P	Yanyan Li	French National Centre of Scientific Research, French National Museum of Natural History	France
P	Yves Louis Janin	French National Centre of Scientific Research, Institut Pasteur	France
P	Philippe Chaignon	University of Strasbourg	France
P	Heike Broetz-Oesterhelt	University of Tübingen	Germany
P	Helge Bode	University of Frankfurt	Germany
P	Jörn Kalinowski	Bielefeld University	Germany
P	Mark Brönstrup	Helmholtz Centre for Infection Research	Germany
P	Achim Hoerauf	Bonn University Medical Center	Germany
P	Andriy Luzhetskyy	Saarland University	Germany
P	Tanja Schneider	University of Bonn	Germany
P	Wolfgang Wohlleben	University of Tübingen	Germany
P	Violetta Cecchetti	University of Perugia	Italy
P	Stefano Donadio	NAICONs Srl	Italy

P	Marco Pieroni	University of Parma	Italy
P	Gilles van Wezel	Leiden University	Netherlands
P	Maarten van Dongen	AMR Insights	Netherlands
P	Marnix Medema	Wageningen University	Netherlands
P	Atanas Atanasov	Polish Academy of Sciences	Poland
P	Rui Moreira	University of Lisbon	Portugal
P	Hrvoje Petkovic	University of Ljubljana	Slovenia
P	Valerie Mizrahi	University of Cape Town	South Africa
P	Olga Genilloud	Fundación MEDINA	Spain
P	Anders Karlén	Uppsala University	Sweden
P	Jörn Piel	ETH Zurich	Switzerland
P	Jean-Louis Reymond	University of Bern	Switzerland
P	Eriko Takano	University of Manchester	United Kingdom
P	Barrie Wilkinson	John Innes Centre	United Kingdom
P	Ian Gilbert	University of Dundee	United Kingdom
P	Ingo Autenrieth	University Hospital Tübingen	Germany

Chosen focal area

- Develop blueprints on: strategic focus, governance, funding/sustainability, infrastructure, engagement, implementation, the unique selling point of the JPIAMR-VRI, and/or addressing innovative “out of the box” ideas
- Develop a Communication and Knowledge Translation Strategy
- Develop a Partnerships Strategy to ensure key stakeholders, including industry and policy makers, and other networks are engaged and coordinate the alignment of other funded Networks
- Develop a plan for a Global Platform for data sharing (e.g. clinical samples/data, scientific information and infrastructures including libraries or catalogues)

Network summary

The IRAADD network includes internationally renowned groups with excellent records of accomplishment in AMR research focussing on early stages of antibiotic discovery and development. This expert team will include natural products researchers, medical microbiologists, bioinformaticians, medicinal chemists and target-based drug designers, as well advisory partners from global alliances focussing on antibiotic development such as DNDi/GARDP and IMI-ENABLE. The partners of the network will set up a cooperative platform that will allow the sharing of scientific research data, translational knowledge and expert advice for the strategic development of new and advanced projects with the aim to take collaborative scientific research in the early stages of antibiotics discovery and development to a new level.

IRAADD believes that such an integrative research network with international outreach will be an important step forward to close the gap in translational drug development, which has been lasting for several decades. IRAADD will represent a consortium of leaders from academia and other sectors who will actively address the worldwide concern of spreading AMR. While this crisis is steadily expanding, research and development of novel antibiotics is inhibited because of underfinanced discovery and development projects prior to the preclinical trial phase, which are essential to provide new and innovative antibiotics for saving patient lives today and in future. In addition, there is currently no network available to leverage the ideas and projects of academic groups, which typically do not move forward towards application.

Thus, our initiative aligns with the current “One Health Action Plan against Antimicrobial Resistance” introduced by the European Commission, which explicitly demands the implementation and support of “research into the development of new antimicrobials” and the establishment of sustainable research networks in this area. However, IRAADD strongly believes that the current situation and available institutions do not efficiently allow for a coordination and coaching especially of academic partners regarding translation of urgently required research on novel antibiotics into clinical use.